12:00 AM
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Leridistim (MPO): Discontinued Phase II/III

Pharmacia Corp. (PHA), Peapack, N.J.
Product: Leridistim (MPO)
Business: Cancer
Therapeutic category: Growth factor
Target: Blood cells
Description: Hematopoietic growth...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >